Study Results of Raltitrexed in Colorectal Cancer
Author Information
Author(s): D Cunningham
Primary Institution: The Royal Marsden Hospital
Hypothesis
Raltitrexed is an effective alternative to 5-FU-based therapy in patients with advanced colorectal cancer.
Conclusion
Raltitrexed shows similar efficacy to 5-FU with a more predictable toxicity profile.
Supporting Evidence
- Raltitrexed had an overall objective response rate of 26%.
- Median survival for raltitrexed was 11.2 months.
- Patients receiving raltitrexed experienced less mucositis compared to those on 5-FU.
- Raltitrexed's toxicity profile is more predictable than that of 5-FU.
- Cost of raltitrexed therapy is similar to that of the Mayo regimen.
Takeaway
Raltitrexed is a new cancer drug that works as well as an older drug called 5-FU but causes fewer side effects.
Methodology
Three phase III clinical trials compared raltitrexed with 5-FU plus leucovorin in patients with advanced colorectal cancer.
Potential Biases
Investigator bias may have affected treatment continuation decisions.
Limitations
The 4.0 mg m-2 dosage arm was discontinued due to toxicity, which may have influenced results.
Participant Demographics
Patients were primarily adults with advanced colorectal cancer, with a mean age around 61 years.
Statistical Information
P-Value
0.01
Confidence Interval
95% CI 9.6-13.1 months
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website